Citius Pharmaceuticals, INC. 8-K Filing
Ticker: CTXR · Form: 8-K · Filed: Dec 1, 2025 · CIK: 1506251
Sentiment: neutral
Filing Stats: 568 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-12-01 17:03:08
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value CTXR The Nasdaq Capital M
Filing Documents
- ea0267562-8k_citius.htm (8-K) — 27KB
- ea026756201ex99-1_citius.htm (EX-99.1) — 36KB
- ea026756201ex99-2_citius.htm (EX-99.2) — 42KB
- ex99-1_001.jpg (GRAPHIC) — 1055KB
- ex99-1_002.jpg (GRAPHIC) — 1327KB
- ex99-1_003.jpg (GRAPHIC) — 382KB
- ex99-1_004.jpg (GRAPHIC) — 407KB
- ex99-1_005.jpg (GRAPHIC) — 502KB
- ex99-1_006.jpg (GRAPHIC) — 564KB
- ex99-1_007.jpg (GRAPHIC) — 543KB
- ex99-1_008.jpg (GRAPHIC) — 632KB
- ex99-1_009.jpg (GRAPHIC) — 627KB
- ex99-1_010.jpg (GRAPHIC) — 499KB
- ex99-1_011.jpg (GRAPHIC) — 317KB
- ex99-1_012.jpg (GRAPHIC) — 452KB
- ex99-1_013.jpg (GRAPHIC) — 696KB
- ex99-1_014.jpg (GRAPHIC) — 520KB
- ex99-1_015.jpg (GRAPHIC) — 649KB
- ex99-1_016.jpg (GRAPHIC) — 484KB
- ex99-1_017.jpg (GRAPHIC) — 191KB
- ex99-1_018.jpg (GRAPHIC) — 502KB
- ex99-1_019.jpg (GRAPHIC) — 645KB
- ex99-1_020.jpg (GRAPHIC) — 746KB
- ex99-1_021.jpg (GRAPHIC) — 375KB
- ex99-1_022.jpg (GRAPHIC) — 519KB
- ex99-1_023.jpg (GRAPHIC) — 493KB
- ex99-1_024.jpg (GRAPHIC) — 175KB
- ex99-1_025.jpg (GRAPHIC) — 465KB
- ex99-1_026.jpg (GRAPHIC) — 162KB
- ex99-1_027.jpg (GRAPHIC) — 322KB
- ex99-1_028.jpg (GRAPHIC) — 1057KB
- ex99-2_001.jpg (GRAPHIC) — 14KB
- ex99-2_002.jpg (GRAPHIC) — 46KB
- 0001213900-25-116760.txt ( ) — 21447KB
- ctxr-20251201.xsd (EX-101.SCH) — 3KB
- ctxr-20251201_lab.xml (EX-101.LAB) — 33KB
- ctxr-20251201_pre.xml (EX-101.PRE) — 22KB
- ea0267562-8k_citius_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 1, 2025, Citius Pharmaceuticals, Inc. posted an updated Corporate Presentation on its website. A copy of the Corporate Presentation is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Other Events
Item 8.01 Other Events. On December 1, 2025, Citius Oncology, Inc. (Nasdaq: CTOR), our majority-owned subsidiary, issued a press release announcing the commercial launch of LYMPHIR (denileukin diftitox-cxdl), a novel IL-2 receptor-directed fusion protein approved by the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Corporate Presentation of December 2025. 99.2 Press release issued by Citius Oncology, dated December 1, 2025 104 Cover Page Interactive Date File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CITIUS PHARMACEUTICALS, INC. Date: December 1, 2025 /s/ Leonard Mazur Leonard Mazur Chairman and Chief Executive Officer 2